Drugs.com - New Drug Approvals

Novartis Receives Third FDA Approval for Oral Fabhalta (iptacopan), the First and Only Treatment Approved in C3 Glomerulopathy

Basel, March 20, 2025 – Novartis today announced that oral Fabhalta (iptacopan) has received U.S. Food and Drug Administration (FDA) approval for the treatment of adults with C3 glomerulopathy (C3G), to reduce proteinuria, making it the first...

Mar 24, 2025 - 05:30
 0
Novartis Receives Third FDA Approval for Oral Fabhalta (iptacopan), the First and Only Treatment Approved in C3 Glomerulopathy
Basel, March 20, 2025 – Novartis today announced that oral Fabhalta (iptacopan) has received U.S. Food and Drug Administration (FDA) approval for the treatment of adults with C3 glomerulopathy (C3G), to reduce proteinuria, making it the first...
Read More

Tags:

Previous Article

Weak February retail recovery signals cautious US consumers: TCB

Next Article

On and Boiler Room Debut Clubhouse Nights Miami

Related Posts

FDA Approves Journavx (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain

FDA Approves Journavx (suzetrigine), a First-in-Class T...

Feb 9, 2025  0

FDA Grants Accelerated Approval to Bizengri (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer

FDA Grants Accelerated Approval to Bizengri (zenocutuzu...

Feb 9, 2025  0

FDA Approves Crenessity (crinecerfont) for the Treatment of Children and Adults with Classic Congenital Adrenal Hyperplasia

FDA Approves Crenessity (crinecerfont) for the Treatmen...

Feb 9, 2025  0